Edwards Names Theodora Mistras as CFO

Why It Matters

The appointment fills a year‑long CFO vacancy, reinforcing financial leadership as Edwards scales its heart‑valve portfolio and signals stability to the market.

Key Takeaways

• Mistras joins Edwards after two years as Viatris CFO
• Replaces long‑time CFO Scott Ullem, who becomes strategic adviser
• Brings investment banking background from Citigroup and Goldman Sachs
• Analysts expect smooth transition, no impact on financial outlook
• Wall Street sees appointment as positive, ending CFO vacancy

Pulse Analysis

Edwards Lifesciences, a leading developer of transcatheter heart‑valve technologies, has been riding a wave of robust demand for its TAVR (transcatheter aortic valve replacement) products. The company’s recent upgrade of its 2026 sales‑growth outlook reflects not only strong clinical adoption but also a strategic push into adjacent cardiac care segments. In this growth phase, the CFO role is pivotal for capital allocation, managing R&D spend, and navigating regulatory reimbursement landscapes that directly affect revenue streams.

Theodora “Doretta” Mistras brings a blend of corporate finance and investment‑banking expertise that is rare among medical‑device CFOs. After steering financial planning at Viatris, a global pharmaceutical firm, she honed deal‑making skills at Citigroup and Goldman Sachs, advising on mergers, capital raises, and strategic restructurings. This dual perspective equips her to optimize Edwards’ balance sheet, evaluate partnership opportunities, and communicate effectively with investors, potentially unlocking new financing avenues for pipeline development.

Wall Street analysts have welcomed the move, noting that the planned transition mitigates the uncertainty that lingered after Scott Ullem’s departure. By ending the CFO vacancy, Edwards can maintain momentum on its growth initiatives without the distraction of leadership turnover. The appointment is likely to bolster confidence among shareholders, support a stable share price, and provide the financial discipline needed as the company expands its product suite and explores international market penetration.